About Aspire Biopharma, Inc. Headquartered in Humacao, Puerto Rico, Aspire Biopharma has developed a disruptive technology through a Novel Soluble Formulation which addresses emergencies, drug ...

Researchers from Florida Atlantic University argue that doctors should consider each patient's individual risk profile rather ...

Recent guidelines have restricted aspirin use in the primary prevention of cardiovascular disease. The American Heart ...

Aspirin use in patients with PIK3CA-mutated colorectal cancer reduces recurrence risk by over 50%. | Drug Discovery And Development ...

Taking aspirin was first linked to a lower risk of colorectal cancer in 1988, but the research into its anti-tumour potential ...

completed its first Good Manufacturing Practice Clinical Batch of its pharmaceutical-grade oral mucosal formulation of aspirin that utilizes Aspire’s fast-acting formulation. Aspire’s GMP ...

Aspirin, one of the world’s most common over-the-counter painkillers, could help fight cancer, a new study, published in Nature, a scientific journal, has discovered. Calling it a ‘Eureka moment’, ...

A new study in mice shows that COX-1 inhibitors, such as aspirin, block a platelet-mediated pathway that cancer cells use to evade immune detection and spread to other tissues. By reducing TXA2 ...

Led by Singapore clinician-scientists, the ASCOLT (Aspirin after completion of standard adjuvant therapy for colorectal cancer) trial is the first phase 3 study to assess the efficacy and safety ...

Aspirin reduces the production of TXA2 ... to treat patients with established metastatic cancer, but when cancer first spreads there’s a unique therapeutic window of opportunity when cancer ...

In mice given aspirin, the frequency of metastases was ... patients with established metastatic cancer, but when cancer first spreads, there’s a unique therapeutic window of opportunity when ...